CR20210095A - Metodo para tratar la epilepsia - Google Patents

Metodo para tratar la epilepsia

Info

Publication number
CR20210095A
CR20210095A CR20210095A CR20210095A CR20210095A CR 20210095 A CR20210095 A CR 20210095A CR 20210095 A CR20210095 A CR 20210095A CR 20210095 A CR20210095 A CR 20210095A CR 20210095 A CR20210095 A CR 20210095A
Authority
CR
Costa Rica
Prior art keywords
fenfluramine
epileptic seizure
racemate
preferred embodiments
embodiments contemplate
Prior art date
Application number
CR20210095A
Other languages
English (en)
Inventor
Jeffrey Paul Bechard
Robin Paul Sherrington
Parisa Karimi Tari
Jean-Jacques Alexandre Cadieux
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CR20210095A publication Critical patent/CR20210095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En determinadas modalidades, la presente descripción está dirigida a los métodos y los usos para tratar a un mamífero que tiene un trastorno convulsivo epiléptico o que está en riesgo de tener un trastorno convulsivo epiléptico, que comprenden la administración de determinados enantiómeros de la fenfluramina aislados descritos en la presente descripción que son sorprendentemente efectivos como fármacos antiepilépticos (AED), a pesar de tener menor potencia anticonvulsiva que el racemato de la fenfluramina, en virtud de que también es menos cardiotóxico que el racemato de la fenfluramina. Las modalidades preferidas contemplan el tratamiento del síndrome de Dravet; otras modalidades preferidas contemplan el tratamiento de otros trastornos convulsivos epilépticos.
CR20210095A 2018-07-27 2019-07-26 Metodo para tratar la epilepsia CR20210095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27
PCT/US2019/043765 WO2020023923A1 (en) 2018-07-27 2019-07-26 Method for treating epilepsy

Publications (1)

Publication Number Publication Date
CR20210095A true CR20210095A (es) 2021-06-01

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210095A CR20210095A (es) 2018-07-27 2019-07-26 Metodo para tratar la epilepsia

Country Status (19)

Country Link
US (1) US20200030260A1 (es)
EP (1) EP3829558A1 (es)
JP (1) JP2021530541A (es)
KR (1) KR20210061332A (es)
CN (1) CN112930175A (es)
AU (1) AU2019310600A1 (es)
BR (1) BR112021001135A2 (es)
CA (1) CA3106031A1 (es)
CL (1) CL2021000196A1 (es)
CO (1) CO2021002087A2 (es)
CR (1) CR20210095A (es)
EA (1) EA202190369A1 (es)
IL (1) IL280128A (es)
MA (1) MA53329A (es)
MX (1) MX2021000987A (es)
PE (1) PE20211065A1 (es)
PH (1) PH12021550176A1 (es)
SG (1) SG11202100682YA (es)
WO (1) WO2020023923A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
IL286391B (en) 2015-12-22 2022-08-01 Zogenix International Ltd Penfluramine preparations and methods for their preparation
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
JP7383012B2 (ja) * 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
US11897995B2 (en) * 2019-07-18 2024-02-13 Basf Se Allophanate based dispersing agent
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023034115A1 (en) * 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (es) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
CN1184957C (zh) 1997-05-07 2005-01-19 盖伦(化学制品)有限公司 用于给药睾酮和睾酮前体的阴道内给药装置
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
PL3261640T3 (pl) * 2015-02-25 2022-10-31 The Regents Of The University Of California Agoniści 5ht do leczenia zaburzeń padaczkowych
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
EA202190369A1 (ru) 2021-06-10
EP3829558A1 (en) 2021-06-09
CO2021002087A2 (es) 2021-04-30
BR112021001135A2 (pt) 2021-04-20
MX2021000987A (es) 2021-06-15
SG11202100682YA (en) 2021-02-25
WO2020023923A1 (en) 2020-01-30
PH12021550176A1 (en) 2021-10-11
CN112930175A (zh) 2021-06-08
AU2019310600A1 (en) 2021-02-11
MA53329A (fr) 2022-03-02
CA3106031A1 (en) 2020-01-30
KR20210061332A (ko) 2021-05-27
IL280128A (en) 2021-03-01
CL2021000196A1 (es) 2021-12-31
US20200030260A1 (en) 2020-01-30
JP2021530541A (ja) 2021-11-11
PE20211065A1 (es) 2021-06-09

Similar Documents

Publication Publication Date Title
PH12021550176A1 (en) Method for treating epilepsy
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
PH12019500177A1 (en) Treatment and prevention of sleep disorders
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2010003548A (es) Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
PH12020551427A1 (en) Epinephrine spray formulations
MX2022003194A (es) Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
WO2019058261A9 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
EA201991650A1 (ru) Способы лечения неврологических расстройств
AU2017261286A1 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
WO2016127059A3 (en) Light inhibitors for scleroderma and skin fibrotic disease treatment
MX2022009384A (es) Usos terapeuticos de la tirzepatida.
IN2013DN11328A (es)
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
Chen et al. Effect of intracranial administration of ethosuximide in rats with spontaneous or pentylenetetrazol‐induced spike‐wave discharges
MX2022014912A (es) Tratamiento del trastorno del espectro autista con cannabidiol.
MX2022013140A (es) Tratamiento de afecciones asociadas con la hormona tiroidea.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2021014987A (es) Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2021005189A (es) Uso de tivozanib para tratar sujetos con cancer refractario.
EA202092472A1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств